Centromere B Antibody is diagnostic for the form of scleroderma known as CREST (calcinosis, Raynaud's phenomenon, esophageal immotility, sclerodactyly, and telangiectasia).

With a high specificity and a prevalence of 80 to 95%, antibodies against centromeres are pathognomonic for the limited form of progressive systemic sclerosis and can be detected even before the onset of the disease. If the corresponding clinical indication is given, the quantitative determination of antibodies with a monospecific test system, e.g. the Anti-Centromeres ELISA, is recommended.

The "Anti-Cerebellum" marker is a crucial test component designed to detect autoantibodies targeting the cerebellum, which is a part of the brain responsible for coordinating voluntary movements, including posture, balance, coordination, and speech. The presence of these autoantibodies can indicate an autoimmune response against the cerebellum, potentially leading to neurological disorders such as cerebellar ataxia. This condition is characterized by difficulties in balance, movement, and possibly affecting speech and eye movements, profoundly impacting an individual's quality of life. 

The marker "Anti-Chromatin Ab, IgG (RDL)" refers to a specific type of blood test that detects antibodies called immunoglobulin G (IgG) that are directed against chromatin. Chromatin is a complex of DNA and proteins found in the nucleus of our cells, and it plays a critical role in packaging DNA into a compact, manageable form, and in regulating gene expression. The presence of anti-chromatin antibodies, like those detected by this test, is significant because they are commonly associated with certain autoimmune disorders, particularly systemic lupus erythematosus (SLE).

Anti-cN-1A (NT5c1A) antibodies are a specific biomarker crucial in the diagnosis and understanding of Inclusion Body Myositis (IBM), a progressive and chronic inflammatory muscle disorder. These antibodies target the protein 5'-nucleotidase 1A (NT5c1A), which plays a role in purine metabolism. The presence of Anti-cN-1A (NT5c1A) antibodies is increasingly recognized as a distinctive serological marker for IBM, distinguishing it from other inflammatory myopathies. IBM is characterized by progressive muscle weakness and atrophy, primarily affecting the quadriceps and forearm muscles. Unlike other myositis forms, IBM is generally resistant to conventional immunosuppressive therapies, making its early and accurate diagnosis through biomarkers like Anti-cN-1A (NT5c1A) particularly important for patient management.

Anti-Contactin-associated protein-like 2 (CASPR2) antibodies, including both IgG and IgA classes, are autoantibodies targeting the CASPR2 protein, a component of the voltage-gated potassium channel complex located in the nervous system. The presence of these antibodies is associated with a spectrum of neurological conditions, often termed CASPR2-antibody associated syndromes, which include neuromyotonia (also known as Isaac's syndrome), Morvan syndrome, and autoimmune forms of limbic encephalitis.

Patients with anti-CASPR2 antibodies can present with various symptoms depending on the affected region of the nervous system. In neuromyotonia, symptoms may include muscle twitching, cramps, and stiffness, whereas limbic encephalitis is characterized by memory loss, confusion, seizures, and sometimes psychiatric symptoms. Morvan syndrome is distinguished by a combination of neuromyotonia and encephalitis symptoms, along with autonomic dysfunction like sleep disturbances, sweating, and cardiac irregularities.

Anti-Contactin-associated protein-like 2 (CASPR2) antibodies of the IgM class are less commonly reported compared to their IgG counterparts but represent an important aspect of the immune response in certain autoimmune neurological disorders. CASPR2 is a cell adhesion molecule that plays a significant role in the proper functioning of the nervous system, particularly in the juxtaparanodal regions of myelinated axons, where it helps to cluster potassium channels. These potassium channels are crucial for maintaining the electrical excitability of nerve cells. When anti-CASPR2 IgM antibodies target this protein, they can disrupt normal neuronal function, leading to a range of clinical manifestations.

Anti-CV2 antibodies, encompassing both IgG and IgA immunoglobulin classes, target a neuronal protein known as CRMP-5 (Collapsin Response Mediator Protein 5). These antibodies are typically associated with paraneoplastic neurological syndromes (PNS), a group of disorders that arise from the immune system's response to certain cancers. The presence of anti-CV2 antibodies can lead to a variety of neurological manifestations, ranging from cerebellar ataxia, limbic encephalitis, to peripheral neuropathies, and less frequently, myelopathies.

Anti CV2 antibodies are a group of antibodies that react with a 66 kd brain protein belonging to the family of CRMP proteins. The manifestations associated with anti CV2 antibodies include cerebellar degeneration, uveitis, and peripheral neuropathy, and mixed axonal and demyelinating peripheral neuropathy.

The anti-dsDNA test identifies the presence of these autoantibodies in the blood.

The test for anti-dsDNA, along with other autoantibody tests, may be used to help establish a diagnosis of lupus and distinguish it from other autoimmune disorders.

The anti-double-stranded DNA antibody (anti-dsDNA) is a specific type of ANA antibody found in about 30% of people with systemic lupus. Less than 1% of healthy individuals have this antibody, making it helpful in confirming a diagnosis of systemic lupus. The absence of anti-dsDNA, however, does not exclude a diagnosis of lupus. 

The presence of anti-dsDNA antibodies often suggests more serious lupus, such as lupus nephritis (kidney lupus). When the disease is active, especially in the kidneys, high amounts of anti-DNA antibodies are usually present. However, the anti-dsDNA test cannot be used to monitor lupus activity, because anti-dsDNA can be present without any clinical activity. Three tests are currently used to detect anti-dsDNA antibodies, namely enzyme-linked immunosorbent assay (ELISA), the Crithidia luciliae immunofluorescence test, and a test called radioimmunoassay.

Low to moderate levels of the autoantibody may be seen with other autoimmune disorders, such as Sjögren syndrome and mixed connective tissue disease (MCTD).

Anti-Deamidated Gliadin IgA (DGP IgA) is a key marker for detecting celiac disease by measuring IgA antibodies against gluten fragments (deamidated gliadin peptides). It’s especially useful for identifying early-stage disease or confirming unclear results from other tests like tTG IgA. Elevated DGP IgA indicates an immune response to gluten, suggesting potential intestinal damage. If levels are high, further testing, such as an intestinal biopsy, may be needed to confirm the diagnosis and guide treatment with a gluten-free diet.

Anti-Deamidated Gliadin IgG (DGP IgG) is a key marker for detecting celiac disease and gluten sensitivity, especially in individuals with IgA deficiency or unclear test results. Elevated DGP IgG levels suggest an immune reaction to gluten, indicating possible celiac disease or non-celiac gluten sensitivity. It’s a reliable alternative when standard IgA-based tests are inconclusive. If your DGP IgG is high, consult your healthcare provider for further evaluation, such as additional antibody tests or a biopsy, to confirm the diagnosis and determine if a gluten-free diet is needed.

The anti-dsDNA test identifies the presence of these autoantibodies in the blood.

The test for anti-dsDNA, along with other autoantibody tests, may be used to help establish a diagnosis of lupus and distinguish it from other autoimmune disorders.

The anti-double-stranded DNA antibody (anti-dsDNA) is a specific type of ANA antibody found in about 30% of people with systemic lupus. Less than 1% of healthy individuals have this antibody, making it helpful in confirming a diagnosis of systemic lupus. The absence of anti-dsDNA, however, does not exclude a diagnosis of lupus. 

The presence of anti-dsDNA antibodies often suggests more serious lupus, such as lupus nephritis (kidney lupus). When the disease is active, especially in the kidneys, high amounts of anti-DNA antibodies are usually present. However, the anti-dsDNA test cannot be used to monitor lupus activity, because anti-dsDNA can be present without any clinical activity. Three tests are currently used to detect anti-dsDNA antibodies, namely enzyme-linked immunosorbent assay (ELISA), the Crithidia luciliae immunofluorescence test, and a test called radioimmunoassay.

Low to moderate levels of the autoantibody may be seen with other autoimmune disorders, such as Sjögren syndrome and mixed connective tissue disease (MCTD).

Anti-DNase B is a blood test to look for antibodies to a substance (protein) produced by group A streptococcus. This is the bacteria that cause strep throat.

Negative anti-DNase B and ASO tests or very low titers means that it is unlikely you had a recent strep infection. This is especially true if a sample taken 10 to 14 days later is also negative. Your signs and symptoms are likely due to a cause other than a recent strep infection.

Anti-Dopamine (IgG + IgA) measures the immune system’s activity against dopamine, a key neurotransmitter involved in:

• Mood regulation and motivation
• Cognition and executive function
• Reward and emotional processing
• Motor control and coordination
• Nervous system stress response

The presence of these antibodies suggests the immune system may be reacting to dopamine or dopamine-related structures. This may reflect neuroimmune activation, neurotransmitter dysregulation, or increased permeability in the blood-brain barrier, allowing the immune system to encounter brain-associated molecules.

This test does not diagnose a neurological disease. Instead, it acts as an early immune-based marker of possible dopamine pathway stress or autoimmune-associated neuroinflammation.

A mild elevation in Anti-Dopamine (IgG + IgA) suggests subtle immune activity toward dopamine-related pathways. This may indicate:

• Early-phase neuroimmune signaling
• Mild neurotransmitter stress or imbalance
• Lifestyle or inflammatory strain affecting dopamine pathways

This result does not diagnose a neurological condition.

Supportive steps

• Improve sleep, stress, and circadian rhythm
• Anti-inflammatory diet and omega-3 intake
• Regular exercise to support dopamine production
• Support gut health and fiber intake
• Maintain stable blood sugar
• Ensure adequate protein and key nutrients (B6, folate, iron)

Helpful to monitor, especially with mood, motivation, or cognitive symptoms.

What is Anti-Dopamine Receptor 1 (IgG + IgA)?

The Anti-Dopamine Receptor 1 (D1R) antibodies test measures IgG and IgA antibodies against dopamine receptor 1 (D1R), a key receptor in the brain involved in cognitive function, movement, and motivation. The presence of these antibodies may indicate immune system activity against dopamine receptors, potentially affecting neurological function.

A mildly elevated result for Anti-Dopamine Receptor 1 (IgG + IgA) on the Neural Zoomer Plus panel by Vibrant America suggests a low to moderate immune response targeting dopamine receptor 1 (D1R) in the brain. While not as concerning as a highly elevated result, it may still indicate underlying neuroinflammation, immune dysregulation, or an early-stage autoimmune response.

Possible Implications of a Mild Elevation

1. Early or Low-Grade Autoimmune Activity

   • A mild elevation may suggest the immune system is beginning to recognize dopamine receptors as targets, but the response is not yet severe.
   • Could be associated with mild neuroinflammation or early stages of conditions like autoimmune encephalitis or PANS/PANDAS (in children).

2. Transient Immune Activation

   • A temporary immune response due to a past infection, recent illness, or environmental trigger (e.g., viral infections, toxins, or stress).
   • If IgA is elevated, it may indicate a more recent immune activation, while IgG elevation suggests a longer-term or past immune response.

3. Subclinical Neurological Impact

   • While not necessarily causing overt neurological symptoms, a mild elevation could be linked to brain fog, mild mood changes, anxiety, or subtle cognitive impairments.
   • If symptoms are present, monitoring for changes over time may be beneficial.

4. Blood-Brain Barrier Permeability ("Leaky Brain")

   • Elevated IgA and IgG antibodies against D1R could indicate a compromised blood-brain barrier, allowing immune cells to interact with brain receptors more than usual.
   • May be associated with gut permeability (leaky gut), chronic inflammation, or systemic autoimmunity.

Next Steps for a Mild Elevation

• Retesting in a few months can help determine if the elevation is persistent or transient.
• Assess symptoms – If there are neurological or cognitive issues, further evaluation may be needed.
• Investigate underlying inflammation – Check for infections, gut health issues, or other autoimmune markers.
• Support brain health – Anti-inflammatory approaches (diet, lifestyle changes, and supplements like omega-3s, curcumin, and antioxidants) may help regulate immune activity.